Background Chronic kidney disease–mineral and bone disorder (CKD–MBD) is a common
complication in CKD patients, particularly in those with end-stage renal disease that requires …

Background/Aims: Hyperphosphatemia is common in patients on hemodialysis. The efficacy
of lanthanum carbonate (LC) in the treatment of hyperphosphatemia in these patients …

Purpose We conducted this review to assess the relative efficacy and safety of lanthanum
carbonate versus calcium-based phosphate binders in chronic kidney disease. Methods We …

Background Lanthanum carbonate is a non-aluminum, non-calcium phosphate binder. Its
efficacy and its safety profile up to 1 year have been reported in Japanese hemodialysis …

Background: Lanthanum carbonate, a new phosphate binder, is effective in reducing serum
phosphorus levels in patients with end-stage renal disease. A 1-year extension study to two …

Background: Control of serum phosphate over the long term is essential in patients with end-
stage renal disease. Six-month and 2-year extensions to a 6-month study evaluated the long …

Orally administered lanthanum carbonate (Fosrenol®) dissociates in the acid environment of
the upper gastrointestinal tract to release the cation lanthanum, which then binds dietary …

Background. The majority of patients with end-stage renal disease on dialysis are
hyperphosphataemic. Lanthanum carbonate has been shown to be a highly effective …

Background Lanthanum carbonate (LC) is a non-calcium-containing phosphate binder and
shows a comparable effect with other phosphate binders on hyperphosphatemia in dialysis …

Results After 16 weeks of additive LC treatment, mean serum phosphorus levels decreased
from 7.30±0.90 to 5.71±1.32 mg/dl, without significant changes in serum calcium or intact …